Praluent vs Lisinopril: Combining the Two (Rationale + Risk)

What Each Drug Actually Does

Alirocumab and lisinopril treat two distinct biological problems. Alirocumab targets LDL-cholesterol by neutralizing PCSK9, the protein that destroys hepatic LDL receptors. Lisinopril blocks angiotensin-converting enzyme, lowering angiotensin II and reducing both systemic vascular resistance and aldosterone secretion. Neither drug meaningfully affects the other's primary target.

Alirocumab Mechanism

PCSK9 normally binds to LDL receptors on liver cells and flags them for degradation. Alirocumab is a fully human monoclonal IgG1 antibody that binds PCSK9 in plasma and prevents that receptor destruction. The result is a larger pool of functional LDL receptors, accelerated clearance of circulating LDL particles, and reductions in LDL-C that average 46-62% depending on background statin therapy [1].

The FDA approved alirocumab in July 2015 for adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease (ASCVD) requiring additional LDL lowering beyond what statins provide [2].

Lisinopril Mechanism

Lisinopril inhibits angiotensin-converting enzyme, preventing conversion of angiotensin I to the potent vasoconstrictor angiotensin II. This lowers peripheral vascular resistance and reduces aldosterone-driven sodium retention. Beyond blood pressure, ACE inhibitors reduce ventricular afterload, slow maladaptive cardiac remodeling post-myocardial infarction, and provide renal protection in diabetic nephropathy [3].

Lisinopril has been FDA-approved since 1987 and carries indications for hypertension, heart failure, and post-MI left ventricular dysfunction [4].

The Evidence Base for Each Drug Separately

Before combining any two agents, the evidence for each drug individually must be understood. Both alirocumab and lisinopril have large randomized controlled trial data supporting their cardiovascular benefit, but those benefits operate through separate endpoints.

ODYSSEY OUTCOMES: The Alirocumab Landmark Trial

ODYSSEY OUTCOMES enrolled 18,924 patients who had experienced an acute coronary syndrome 1-12 months before randomization and were already on maximally tolerated statin therapy [5]. Alirocumab 75 mg subcutaneously every two weeks (titrated to 150 mg if needed to achieve LDL-C <25 mg/dL) was compared to placebo over a median follow-up of 2.8 years.

The primary endpoint, a composite of coronary heart disease death, nonfatal MI, fatal or nonfatal ischemic stroke, and unstable angina requiring hospitalization, occurred in 9.5% of the alirocumab group versus 11.1% in the placebo group (hazard ratio 0.85, 95% CI 0.78-0.93, P<0.001) [5]. That is a 15% relative risk reduction in patients already on statin therapy. All-cause mortality was also numerically lower with alirocumab (3.5% vs 4.1%), though the pre-specified hierarchical testing did not achieve significance for that endpoint alone.

Mean LDL-C at 48 weeks was 53.3 mg/dL in the alirocumab arm versus 101.4 mg/dL in placebo, a difference of 48.1 mg/dL [5].

ALLHAT: The Lisinopril Reference Trial

ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) randomized 33,357 high-risk hypertensive patients to chlorthalidone, amlodipine, or lisinopril and followed them for a mean of 4.9 years [6]. The primary outcome was fatal coronary heart disease or nonfatal MI.

Lisinopril showed a 6-year primary outcome rate of 11.4% versus 11.5% for chlorthalidone (relative risk 0.98, 95% CI 0.90-1.07), establishing non-inferiority for coronary events [6]. Lisinopril did produce higher rates of stroke than chlorthalidone in certain subgroups (particularly Black patients), a finding that informs current prescribing guidelines about antihypertensive selection by race and comorbidity [6].

The ACC/AHA 2017 Hypertension Guideline identifies ACE inhibitors as first-line agents for patients with heart failure, post-MI status, high coronary disease risk, or diabetes, all populations that frequently overlap with the patients who also need alirocumab [7].

Why Combining Alirocumab and Lisinopril Makes Clinical Sense

The rationale for combination is straightforward. Atherosclerotic cardiovascular disease is driven by multiple simultaneous processes: dyslipidemia accelerates plaque formation, while hypertension causes endothelial shear stress and promotes plaque rupture. A patient who has had an MI at age 58 with LDL-C of 110 mg/dL on rosuvastatin and a resting BP of 148/92 mmHg has two active disease drivers. Neither drug alone addresses both.

Pathway Independence

Alirocumab does not affect the renin-angiotensin-aldosterone system. Lisinopril does not affect PCSK9 or LDL receptor expression. No pharmacokinetic drug-drug interaction has been identified in the alirocumab prescribing information or in the published literature [2]. The two drugs are metabolized by entirely different routes: alirocumab is a biologic that undergoes proteolytic degradation via standard antibody catabolism pathways, while lisinopril is eliminated renally as unchanged drug [4].

Guideline Alignment

The 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol explicitly states that PCSK9 inhibitors are appropriate add-on therapy for patients with ASCVD whose LDL-C remains above 70 mg/dL on maximally tolerated statin therapy [8]. The same patient population is also the core candidate for an ACE inhibitor per the 2017 ACC/AHA Hypertension Guideline when BP exceeds 130/80 mmHg [7].

The ACC/AHA 2018 guideline states: "For patients with clinical ASCVD who are at very high risk, a PCSK9 inhibitor is recommended if LDL-C is persistently 70 mg/dL or higher" [8]. Lisinopril would then be indicated concurrently if hypertension is present, following standard of care.

Real-World Practice Pattern

Cardiologists managing post-ACS patients frequently prescribe four to six medications simultaneously: a high-intensity statin, aspirin, a beta-blocker, an ACE inhibitor, and in some cases a PCSK9 inhibitor and an SGLT2 inhibitor. Alirocumab plus lisinopril within that regimen is not a novel combination. It is already the de facto standard in guideline-adherent post-ACS care for patients who meet both indications. The practical question is not "should I combine them" but "does this specific patient meet the threshold for alirocumab given the cost and their LDL trajectory."

Risks and Adverse Effects When Combining

The two drugs have non-overlapping adverse effect profiles. That generally makes combination safer, but each drug's own risks must be managed.

Lisinopril-Specific Risks

ACE inhibitor-related angioedema occurs in approximately 0.1-0.7% of patients, with a higher incidence in Black patients (up to 3x higher relative risk compared to white patients) [9]. Patients who develop angioedema must stop lisinopril permanently and should not receive any other ACE inhibitor. An ARB (e.g., losartan or valsartan) would be substituted, which carries an angioedema risk below 0.1% [10].

Hyperkalemia is a concern in patients with CKD or diabetes. In ALLHAT, serum potassium at 2 years was 4.5 mEq/L in the lisinopril arm, compared to 4.4 mEq/L in the chlorthalidone arm [6]. Patients on aldosterone antagonists (e.g., spironolactone) or potassium-sparing diuretics who add lisinopril need potassium monitoring within 1-2 weeks.

A dry cough develops in 5-20% of patients on ACE inhibitors, related to bradykinin accumulation; alirocumab does not contribute to or worsen this [4].

Alirocumab-Specific Risks

Injection-site reactions occurred in 7.2% of alirocumab-treated patients in ODYSSEY OUTCOMES versus 5.1% in placebo [5]. These are typically mild erythema and pruritus. No immune-mediated severe hypersensitivity requiring drug discontinuation occurred in more than 0.5% of patients in the trial program [2].

Neurocognitive adverse events (confusion, memory impairment) were reported as a concern in early PCSK9 inhibitor trials, but the EBBINGHAUS cognitive substudy of FOURIER (N=1,204, testing evolocumab) found no significant cognitive decline at 19 months of follow-up, providing indirect reassurance for the drug class [11].

Hypotension: Is There Additive Risk?

Lisinopril lowers blood pressure; alirocumab does not. There is no additive hypotensive risk from combining them. Patients already on amlodipine plus lisinopril who add alirocumab should not require BP titration adjustments solely because of the alirocumab addition.

Renal Function Monitoring

Lisinopril can cause a rise in serum creatinine of up to 30% in the first weeks of therapy, particularly in patients with bilateral renal artery stenosis or volume depletion [4]. Alirocumab does not affect renal function [2]. A 30% creatinine rise is generally acceptable and even expected with ACE inhibitors as a marker of effective glomerular pressure reduction, but rises above 30% or absolute creatinine above 3.0 mg/dL warrant stopping lisinopril and investigating renal artery stenosis.

Patient Selection: Who Needs Both?

Not every cardiovascular patient needs alirocumab. The drug costs roughly $500-600/month before insurance; generic lisinopril 10 mg tablets cost under $10/month. The decision to add alirocumab on top of an existing lisinopril regimen (or vice versa) depends on meeting specific thresholds.

Indications for Adding Alirocumab to an Existing Lisinopril Regimen

A patient already controlled on lisinopril for post-MI hypertension should be considered for alirocumab if:

• LDL-C remains 70 mg/dL or above despite maximally tolerated statin (rosuvastatin 20-40 mg or atorvastatin 40-80 mg) [8]
• The patient has established ASCVD (prior MI, prior stroke, peripheral artery disease) or heterozygous familial hypercholesterolemia
• Statin intolerance limits LDL reduction, making an injectable alternative necessary

The number needed to treat (NNT) in ODYSSEY OUTCOMES for preventing one major cardiovascular event over 2.8 years was approximately 62 [5], which compares favorably to the NNT of 48 for high-intensity statins in similar post-ACS populations.

When Lisinopril Is Added to an Alirocumab Regimen

A patient started on alirocumab for familial hypercholesterolemia who later develops hypertension or post-MI LV dysfunction should receive an ACE inhibitor as first-line therapy per 2017 ACC/AHA Hypertension Guidelines [7]. There is no reason to delay lisinopril initiation because alirocumab is already in use. The drugs operate on independent targets and have no interaction.

Special Populations

Patients with diabetes and CKD stage 3 (eGFR 30-59 mL/min/1.73m2) are excellent candidates for both drugs. Lisinopril has class I evidence for renoprotection in diabetic nephropathy per ADA Standards of Care [12]. Alirocumab's cardiovascular event reduction applies regardless of diabetes status; in ODYSSEY OUTCOMES, the hazard ratio for major events in the diabetes subgroup was 0.83 (95% CI 0.73-0.95) [5]. Alirocumab is not renally cleared to a significant extent, so dose adjustment is not required even in moderate CKD [2].

Patients with heart failure with reduced ejection fraction (HFrEF) should receive an ACE inhibitor (lisinopril or enalapril) as a guideline-directed medical therapy; if they also have ASCVD and elevated LDL-C, alirocumab is appropriate to add [13].

Should You Switch From Praluent to Lisinopril (or the Reverse)?

These drugs are not interchangeable. Switching implies they serve the same purpose, which they do not. Alirocumab lowers LDL-C. Lisinopril lowers blood pressure and provides cardiac and renal protection. A patient cannot substitute one for the other.

If a prescriber is considering "switching" it likely reflects a misunderstanding of each drug's role, or a cost-driven conversation. If a patient cannot afford alirocumab and the primary concern is LDL-C, the alternative is to intensify statin therapy, add ezetimibe 10 mg daily (which reduces LDL-C by an additional 18-20% and was shown to reduce cardiovascular events in IMPROVE-IT, N=18,144) [14], or explore patient assistance programs from Sanofi/Regeneron before discontinuing alirocumab.

Lisinopril does not lower LDL-C and cannot serve as a PCSK9 inhibitor substitute. Alirocumab does not lower blood pressure and cannot serve as an antihypertensive substitute.

Practical Dosing and Monitoring When Both Are Prescribed

Alirocumab Dosing

Start at 75 mg subcutaneously every two weeks. Measure fasting LDL-C at 4-8 weeks. If LDL-C remains above 70 mg/dL in a very-high-risk patient, uptitrate to 150 mg every two weeks [2]. Alternatively, alirocumab 300 mg monthly (a single injection) is FDA-approved and may improve adherence.

Lisinopril Dosing

For hypertension: start at 10 mg daily, target 10-40 mg daily based on BP response. For post-MI LV dysfunction: start at 2.5-5 mg and titrate to 10 mg daily as tolerated. For heart failure: target dose of 20-40 mg daily has been associated with the best outcomes in trials including ATLAS ACS 2 TIMI 51 [15].

Monitoring Schedule

Check serum potassium, creatinine, and eGFR at baseline and 2-4 weeks after starting or uptitrating lisinopril. Repeat fasting lipid panel 4-8 weeks after each alirocumab dose change. Blood pressure should be measured at each visit. Annual monitoring of these parameters is sufficient once stable.

The Cost and Access Question

The cost disparity between these two drugs is large. Lisinopril 20 mg daily costs approximately $48/year as a generic [4]. Alirocumab 75 mg every two weeks costs approximately $6,000-7,200/year before insurance coverage [2]. Both Sanofi and Regeneron offer co-pay assistance programs that can reduce out-of-pocket costs for insured patients to under $0-10/injection for eligible individuals.

Medicare Part D coverage for alirocumab has improved since 2023 formulary changes, but prior authorization remains common. The Institute for Clinical and Economic Review (ICER) estimated that alirocumab is cost-effective at prices below $4,500/year for very-high-risk patients, which is below current list price but achievable with discounts [16].

Lisinopril is on virtually every insurance formulary as a Tier 1 generic. The cost differential should not drive a decision to avoid alirocumab in a post-ACS patient with LDL-C of 95 mg/dL on rosuvastatin 40 mg, but it is a practical factor in shared decision-making.

Summary of Combination Rationale

Alirocumab and lisinopril address two independent cardiovascular risk factors: hypercholesterolemia and hypertension. Post-ACS patients frequently carry both risk factors. The 2018 AHA/ACC Cholesterol Guideline and the 2017 AHA/ACC Hypertension Guideline both independently support each drug in overlapping patient populations. No pharmacokinetic or pharmacodynamic interaction exists between them. The combination is appropriate, evidence-based, and already the standard of care in guideline-adherent post-ACS management for patients who meet both drug's indications.

The ACC/AHA 2017 Hypertension Guideline defines hypertension as BP 130/80 mmHg or above, meaning that most post-ACS patients monitored in cardiology practice will have a lisinopril indication. ODYSSEY OUTCOMES showed that alirocumab reduces the absolute risk of a recurrent major cardiovascular event by approximately 1.6 percentage points over 2.8 years in patients already on statins [5]. Both effects are additive.

For a post-ACS patient on rosuvastatin 40 mg daily with LDL-C of 88 mg/dL and BP of 142/90 mmHg, the correct prescribing decision is not alirocumab or lisinopril. It is alirocumab and lisinopril, titrated to LDL-C <70 mg/dL and BP <130/80 mmHg per current guidelines [7, 8].